YD Bio Limited AI Stock Analysis
Want to see YDES full AI Analyst Report?
YD Bio Limited (YDES) AI Stock Analysis
YD Bio Limited
(NASDAQ:YDES)
YDES scores near the absolute bottom of the range, heavily penalized by severe insolvency risks, escalating cash burn, and a deeply negative equity position. These fundamental weaknesses are compounded by unprofitability and bearish technical trends, making the stock highly speculative and completely reliant on immediate external capital.
YD Bio Limited (YDES) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $343.53M
- Dividend Yield
- ―
- Average Volume (3M)
- 310.34K
- Price to Earnings (P/E)
- -40.4
- Beta (1Y)
- 0.20
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- US
- Employees
- 14
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
YD Bio Limited Business Overview & Revenue Model
Company Description
YD Bio Limited, a biopharmaceutical company, focuses on regulated diagnostics, life science clinical services, and healthcare product commercialization in the United States and Taiwan. The company offers eye disease treatment products, 3D LensMate Ar...
YD Bio Limited Financial Statement Overview
Summary
YD Bio faces critical financial distress with massive net losses, negative stockholders' equity, and accelerating cash burn, highlighting severe structural profitability issues and solvency risks.
Income Statement
15Very NegativeBalance Sheet
20Very NegativeCash Flow
10Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 596.82K | 510.36K | 350.13K | 0 | 0 |
| Gross Profit | 0 | -42.15K | 155.36K | 153.44K | 0 | 0 |
| EBITDA | -2.99M | -8.10M | -1.28M | 22.25K | 3.79M | 8.70M |
| Net Income | -2.97M | -8.31M | -1.41M | 13.56K | 3.79M | 8.70M |
Balance Sheet | ||||||
| Total Assets | 2.95M | 13.78M | 6.86M | 321.21K | 17.93M | 118.06M |
| Cash, Cash Equivalents and Short-Term Investments | 6,312 | 6.01M | 3.13M | 87.10K | 14.13K | 5,403 |
| Total Debt | 0 | 6,764 | 22.55K | 47.58K | 0 | 0 |
| Total Liabilities | 19.00M | 16.64M | 273.98K | 298.22K | 6.74M | 9.11M |
| Stockholders Equity | -16.05M | -2.86M | 6.59M | 22.99K | 11.20M | 108.96M |
Cash Flow | ||||||
| Free Cash Flow | -1.18M | -8.04M | -4.75M | -55.95K | -3.02M | -688.42K |
| Operating Cash Flow | -1.18M | -6.60M | -1.84M | -55.66K | -3.02M | -688.41K |
| Investing Cash Flow | 7.95M | -1.44M | -2.90M | -290 | 100.38M | -1.15M |
| Financing Cash Flow | -6.81M | 10.87M | 7.73M | 113.89K | -97.34M | 1.15M |
YD Bio Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For YDES, the sentiment is Negative. The current price of 4.85 is below the 20-day moving average (MA) of 5.72, below the 50-day MA of 5.57, and below the 200-day MA of 5.14, indicating a bearish trend. The MACD of -0.19 indicates Positive momentum. The RSI at 42.71 is Neutral, neither overbought nor oversold. The STOCH value of 17.29 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for YDES.
YD Bio Limited Risk Analysis
YD Bio Limited disclosed 61 risk factors in its most recent earnings report. YD Bio Limited reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksYD Bio Limited Peers Comparison
Overall Rating
YDES39Underperform
SCNI39Underperform
Financial Indicators
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| YDES | YD Bio Limited | 4.85 | -3.60 | -42.60% | |
| SCNI | Scinai Immunotherapeutics Ltd. Sponsored Adr | 0.37 | -8.33 | -95.78% | |
| ADTX | Aditxt, Inc. | 0.04 | -602.60 | -99.99% | |
| SPRC | SciSparc Ltd. | 0.27 | -21.42 | -98.76% | |
| CDT | Cdt Equity Inc. | 0.34 | -206249.66 | -100.00% | |
| VRAX | Virax Biolabs Group Ltd. Class A | 0.43 | -8.92 | -95.40% |
YD Bio Limited Corporate Events
YD Bio Files First-Half 2026 Results, Reports Improved Equity Position
YD Bio Limited has filed its unaudited interim consolidated financial statements for the six months ended June 30, 2026, showing total assets of about $10.1 million and a swing in shareholders’ equity from a deficit of $2.9 million at year-end 2025 t...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 13, 2026
